Benzinga | Aug 16, 2021 04:48PM EDT

Inhibikase Therapeutics Q2 EPS $(0.22) Down From $(0.05) YoY, Sales $1.36M Up From $219.59K YoY

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.22) per share. This is a 340 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $1.36 million in sales this quarter. This is a 520.72 percent increase over sales of $219.59 thousand the same period last year.